Introduction {#section1-1076029618823288}
============

Venous thromboembolism (VTE) is one of the major complications of many malignancies. Patients with a malignancy have an approximately 4- to 6.7-fold increased risk of VTE compared to the general population.^[@bibr1-1076029618823288][@bibr2-1076029618823288]--[@bibr3-1076029618823288]^ Because VTE increases in-hospital morbidity, cost of hospitalization, and possibly mortality, it is an important problem in patients with malignancies.^[@bibr4-1076029618823288][@bibr5-1076029618823288]--[@bibr6-1076029618823288]^

The incidence of VTE in malignancy is influenced by cancer characteristics, including the type and stage of tumor, as well as the length of time from diagnosis.^[@bibr3-1076029618823288],[@bibr7-1076029618823288],[@bibr8-1076029618823288]^ Previous large population studies showed that the incidence of VTE was highest in the first few months after cancer diagnosis, then decreased over time.^[@bibr3-1076029618823288],[@bibr8-1076029618823288]^ In addition, several large-scale studies reported that patients diagnosed with metastatic gastrointestinal, bladder, uterine, and kidney cancer had a 6 to 25 times increased incidence of VTE, compared to those with other cancer types or localized disease.^[@bibr3-1076029618823288],[@bibr9-1076029618823288],[@bibr10-1076029618823288]^ As the risk of VTE varies according to cancer features, appropriate prophylaxis and monitoring for VTE may depend on a patient's disease status.

Renal cell carcinoma (RCC) is associated with an increased risk of VTE, with an incidence rate of approximately 1.3% to 3.8% during 2-year follow-up.^[@bibr9-1076029618823288]^ In addition, migration of tumor into the renal vein and inferior vena cava, resulting in tumor thrombus formation, is a unique characteristic of RCC, found in approximately 4% to 10% of patients with this tumor.^[@bibr11-1076029618823288]^ Furthermore, similar to lymph node involvement or metastasis, thrombus has been found to have an important predictive role in patient prognosis.^[@bibr12-1076029618823288],[@bibr13-1076029618823288]^

Venous tumor thrombus can activate the vascular endothelium and disturb venous blood flow, which may increase the risk of VTE.^[@bibr14-1076029618823288],[@bibr15-1076029618823288]^ However, the clinical effects of tumor thrombus on VTE have not been well established, and few studies have reported significantly increased risks of VTE in patients with tumor thrombus.^[@bibr16-1076029618823288],[@bibr17-1076029618823288]^

The aims of this study were to elucidate the influence of tumor thrombus on VTE development and survival in patients who underwent surgical management for RCC. Additionally, we sought to identify other risk factors for VTE, such as patient age, hemogram results, and levels of inflammatory markers.

Materials and Methods {#section2-1076029618823288}
=====================

Patient Characteristics and Data Collection {#section3-1076029618823288}
-------------------------------------------

We enrolled patients with pathologically confirmed RCC who underwent surgery at Seoul National University Hospital between September 1999 and August 2015. All patients underwent either radical or partial nephrectomy; for those suspected of having tumor thrombus based on preoperative image studies (eg, computed tomography \[CT\]), thrombectomy was also performed.

Clinical information regarding patients was retrospectively collected through a medical records review. The data included patient baseline characteristics, tumor histology and characteristics, tumor stage at the time of surgery, the presence or absence of tumor thrombus, and results of preoperative laboratory tests, including C-reactive protein (CRP), hemoglobin, and platelet, neutrophil, and lymphocyte counts. Tumor thrombus was defined as the presence of tumor thrombus confirmed by pathology after surgery. The neutrophil-to-lymphocyte ratio (NLR) was calculated by dividing the neutrophil count by the lymphocyte count. Postoperative VTE events were defined as pulmonary embolism (PE) or deep vein thrombosis (DVT). They were diagnosed using angiography, CT, and Doppler sonography. The value of laboratory tests was obtained before surgery.

Study End Points {#section4-1076029618823288}
----------------

The primary objective of this study was to evaluate the incidence and risk factors for VTE in patients with RCC who underwent surgery. We specifically evaluated the association between tumor thrombus and the occurrence of VTE. The secondary objective was to evaluate survival outcomes and to determine prognostic factors for survival.

Statistical Analysis {#section5-1076029618823288}
--------------------

The cumulative incidence of VTE was calculated from the date of surgery to the detection of thromboembolism by diagnostic imaging. Progression-free survival (PFS) was defined as time from the date of surgery to the date at which disease progression was confirmed by imaging. Overall survival (OS) was defined as the time from the date of surgery to the date of either death or last follow-up. The incidence of VTE was analyzed using Pearson χ^2^ or Fisher exact test, as appropriate. Kaplan-Meier curves were used to analyze the cumulative incidences of VTE, PFS, and OS. Cutoff values of the continuous variables were either normal values (hemoglobin, platelet count, and CRP) or median values (age and NLR). Variables with *P* values \<.05 in univariable analysis were considered for the multivariable analysis, which was performed using the logistic regression model and Cox proportional hazard model. All statistical tests were 2 sided; significance was defined as *P* \<.05. All analyses were performed using IBM SPSS version 23.0 (IBM, Armonk, New York).

Ethical Considerations {#section6-1076029618823288}
----------------------

This study was approved by the Seoul National University Hospital institutional review board (H-1710-095-895). It was conducted in accordance with the Declaration of Helsinki guidelines for biomedical research.

Results {#section7-1076029618823288}
=======

Patient Baseline Characteristics {#section8-1076029618823288}
--------------------------------

From September 1999 to August 2015, a total of 2762 patients underwent surgery. Radical nephrectomy was performed in 1436 (52.0%) patients; of these, 921 (33.3%) underwent open surgery, 367 (13.3%) underwent transperitoneal laparoscopic surgery, 124 (4.5%) underwent hand-assisted laparoscopic surgery, 15 (0.5%) underwent retroperitoneal laparoscopic surgery, and 9 (0.3%) underwent robot-assisted surgery. Partial nephrectomy was performed in 1326 (48.0%) patients; of these, 1038 (37.6%) underwent open surgery, 201 (7.3%) underwent robot-assisted surgery, 70 (2.5%) underwent transperitoneal laparoscopic surgery, 15 (0.5%) underwent retroperitoneal laparoscopic surgery, and 2 (0.1%) underwent hand-assisted laparoscopic surgery. Baseline characteristics of the patients are summarized in [Table 1](#table1-1076029618823288){ref-type="table"}.

###### 

Baseline Characteristics of Patients.^a^

![](10.1177_1076029618823288-table1)

  Variables                                       Values
  ----------------------------------------------- ----------------------------------------
  Age, years, median (range)                      56.0 (10.0-87.0)
  Gender, n (%)                                   
   Male                                           1927 (69.8)
   Female                                         835 (30.2)
  Smoking, n (%)                                  
   Yes                                            429 (15.5)
   No                                             2319 (84.0)
   Not evaluated                                  14 (0.5)
  ECOG, n (%)                                     
   0                                              1934 (70.0)
   1                                              693 (25.1)
   2                                              116 (4.2)
   Not evaluated                                  19 (0.7)
  Histology, n (%)                                
   Clear cell type                                2163 (78.3)
   Papillary type                                 289 (10.5)
   Chromophobe type                               215 (7.8)
   Others                                         95 (3.4)
  Pathologic T stage                              
   1                                              2090 (75.7)
   2                                              255 (9.2)
   3                                              316 (11.4)
   4                                              17 (0.6)
   Not evaluated                                  84 (3.0)
  Pathologic N stage                              
   Negative                                       310 (11.2)
   Positive                                       2431 (88.0)
   Not evaluated                                  21 (0.8)
  Clinical M stage                                
   Negative                                       2577 (93.3)
   Positive                                       154 (5.6)
   Not evaluated                                  31 (1.1)
  Tumor thrombosis, n (%)                         
   No thrombosis                                  2589 (93.7)
   Renal vein thrombosis                          119 (4.3)
   Thrombosis involved IVC below the diaphragm    25 (0.9)
   Thrombosis involved IVC above the diaphragm    9 (0.3)
   Not evaluated                                  20 (0.7)
  Tumor extrusion, n (%)                          
   Exophytic                                      1253 (45.4)
   Mesophytic                                     747 (27.0)
   Endophytic                                     707 (25.6)
   Not evaluated                                  55 (2.0)
  Preoperative hemoglobin, g/dL, median (range)   13.9 (4.5-21.6)
  Preoperative platelet, /μL, median (range)      229 × 10^3^ (17.3 × 10^3^-747 × 10^3^)
  Preoperative NLR, median (range)                1.87 (0.02-80.6)
  Preoperative CRP, mg/dL, median (range)         0.12 (0.0-25.5)

Abbreviations: CRP, C-reactive protein; ECOG, Eastern Cooperative Oncology Group; IVC, inferior vena cava; NLR, neutrophil-to-lymphocyte ratio.

^a^ N = 2762.

Incidence of VTE {#section9-1076029618823288}
----------------

The median follow-up duration of all 2762 patients was 39.0 months (95% confidence interval \[CI\], 37.1-41.0 months). The 1- and 5-year cumulative incidences of VTE in all patients were 0.5% ± 0.1% and 1.5% ± 0.3%, respectively ([Figure 1A](#fig1-1076029618823288){ref-type="fig"}). During follow-up, 28 VTE events occurred in 28 patients (1.0%); DVT occurred in 13 patients and PE occurred in 15 patients. The median time to occurrence of VTE was 9.4 months (95% CI, 0.0-23.9 months) after surgery.

![Cumulative incidence of venous thromboembolism (VTE) in patients with renal cell carcinoma: (A) in all study patients, (B) according to the presence or absence of tumor thrombus (5-year cumulative incidence: 1.0% vs 10.4%, *P* \< .001), (C) according to age (5-year cumulative incidence: 2.8% vs 0.1%, *P* \< .001), and (D) according to C-reactive protein (5-year cumulative incidence: 6.0% vs 0.1%, *P* \< .001).](10.1177_1076029618823288-fig1){#fig1-1076029618823288}

In univariable analysis, older age (≥60 years), advanced T stage, the presence of tumor thrombus, and an increased preoperative platelet count (\>400 × 10^3^/μL) and CRP (\>0.5 mg/dL) were associated with a significantly increased incidence of VTE when all patients were considered (*P \<* .05 for all factors; [Table 2](#table2-1076029618823288){ref-type="table"}; cumulative incidence of VTE: [Figure 1B](#fig1-1076029618823288){ref-type="fig"} for tumor thrombus, [Figure 1C](#fig1-1076029618823288){ref-type="fig"} for age, and [Figure 1D](#fig1-1076029618823288){ref-type="fig"} for CRP). In subgroup analysis of patients who were not diagnosed with stage IV at the initial diagnosis, older age (≥60 years), the presence of tumor thrombus, and an increased preoperative platelet count (\>400 × 10^3^/μL) and CRP (\>0.5 mg/dL) were associated with an increased incidence of VTE in univariable analysis (*P \<* .05 for all factors; [Table 3](#table3-1076029618823288){ref-type="table"}).

###### 

Odds Ratios (ORs) and *P* Values of Thromboembolic Events in Univariable and Multivariable Analyses (Total Patients).

![](10.1177_1076029618823288-table2)

  Characteristics              No Thrombosis (%)   Thrombosis (%)   *P* Value (Univariable Analysis)   OR      95% CI         *P* Value (Multivariable Analysis)
  ---------------------------- ------------------- ---------------- ---------------------------------- ------- -------------- ------------------------------------
  Age, years                                                                                                                  
   ≥60                         1118/2734 (40.9)    21/28 (75.0)     \<.001                             8.608   1.845-         .006
   \<60                        1616/2734 (59.1)    7/28 (25.0)                                         1       40.152         
  Gender                                                                                                                      
   Male                        1907/2734 (69.8)    20/28 (71.4)     1.000                                                     
   Female                      827/2734 (30.2)     8/28 (28.6)                                                                
  Smoking                                                                                                                     
   Yes                         425/2720 (15.6)     4/28 (14.3)      .913                                                      
   No                          2295/2720 (84.4)    24/28 (85.7)                                                               
  ECOG                                                                                                                        
   0                           1918/2717 (70.6)    16/26 (61.5)     .162                                                      
   1                           686/2717 (25.2)     7/26 (26.9)                                                                
   2                           113/2717 (4.2)      3/26 (11.5)                                                                
  Histology                                                                                                                   
   Clear cell type             2144/2734 (78.4)    19/28 (67.9)     .300                                                      
   Papillary type              283/2734 (10.4)     6/28 (21.4)                                                                
   Chromophobe                 213/2734 (7.8)      2/28 (7.1)                                                                 
   Others                      94/2734 (3.4)       1/28 (3.6)                                                                 
  T stage                                                                                                                     
   1                           2078/2651 (78.4)    12/27 (44.4)     \<.001                             1                      .923
   2                           249/2651 (9.4)      6/27 (22.2)                                         1.265   0.211-7.588    .797
   3                           309/2651 (11.7)     7/27 (25.9)                                         0.666   0.102-4.364    .671
   4                           15/2651 (0.6)       2/27 (7.4)                                          0.930   0.047-18.398   .962
  N or M stage                                                                                                                
   N0M0                        278/2734 (10.2)     4/28 (14.3)      .523                                                      
   N+ or M+                    2456/2734 (89.8)    24/28 (85.7)                                                               
  Tumor thrombus                                                                                                              
   No thrombus                 2571/2714 (94.7)    18/28 (64.3)     \<.001                             1       1.480-45.004   .016
   Thrombus                    143/2714 (5.3)      10/28 (35.7)                                        8.160                  
  Tumor extrusion                                                                                                             
   Exophytic                   1242/2681 (46.3)    11/26 (42.3)     .722                                                      
   Mesophytic                  738/2681 (27.5)     9/26 (34.6)                                                                
   Endophytic                  701/2681 (26.1)     6/26 (23.1)                                                                
  Preoperative Hb, g/dL                                                                                                       
   \>16                        219/2733 (8.0)      2/28 (7.1)       1.000                                                     
   ≤16                         2514/2733 (92.0)    26/28 (92.9)                                                               
  Preoperative platelet, /μL                                                                                                  
   \>400 × 10^3^               88/2732 (3.2)       4/28 (14.3)      .013                               2.232   0.503-9.907    .291
   ≤400 × 10^3^                2644/2732 (96.8)    24/28 (85.7)                                        1                      
  Preoperative NLR                                                                                                            
   ≥1.87                       1358/2729 (49.8)    19/28 (67.9)     .060                                                      
   \<1.87                      1371/2729 (50.2)    9/28 (32.1)                                                                
  Preoperative CRP, mg/dL                                                                                                     
   \>0.5                       391/1680 (23.3)     11/15 (73.3)     \<.001                             4.144   1.107-15.516   .035
   ≤0.5                        1289/1680 (76.7)    4/15 (26.7)                                         1                      

Abbreviations: CI, confidence interval; CRP, C-reactive protein; ECOG, Eastern Cooperative Oncology Group; Hb, hemoglobin; NLR, neutrophil-to-lymphocyte ratio.

###### 

Odds Ratios (ORs) and *P* Values of Thromboembolic Events in Univariable and Multivariable Analyses.^a^

![](10.1177_1076029618823288-table3)

  Characteristics              No Thrombosis (%)   Thrombosis (%)   *P* Value (Univariable Analysis)   OR       95% CI          *P* Value (Multivariable Analysis)
  ---------------------------- ------------------- ---------------- ---------------------------------- -------- --------------- ------------------------------------
  Age, years                                                                                                                    
   ≥60                         662/1609 (41.1)     10/13 (76.9)     .011                               14.935   1.671-133.529   .016
   \<60                        947/1609 (58.9)     3/13 (23.1)                                         1                        
  Gender                                                                                                                        
   Male                        1101/1609 (68.4)    8/13 (61.5)      .595                                                        
   Female                      508/1609 (31.6)     5/13 (38.5)                                                                  
  Smoking                                                                                                                       
   Yes                         242/1605 (15.1)     2/13 (15.4)      .921                                                        
   No                          1363/1605 (84.9)    11/13 (84.6)                                                                 
  ECOG                                                                                                                          
   0                           1180/1594 (74.0)    10/12 (83.3)     .695                                                        
   1                           361/1594 (22.6)     2/12 (16.7)                                                                  
   2                           53/1594 (3.3)       0                                                                            
  Histology                                                                                                                     
   Clear cell type             1224/1609 (76.1)    7/13 (53.8)      .064                                                        
   Papillary type              176/1609 (10.9)     4/13 (30.8)                                                                  
   Chromophobe                 118/1609 (7.3)      2/13 (15.4)                                                                  
   Others                      91/1609 (5.7)       0                                                                            
  T stage                                                                                                                       
   1                           1235/1528 (80.8)    8/13 (61.5)      .073                                                        
   2                           127/1528 (8.3)      1/13 (7.7)                                                                   
   3                           166/1528 (10.9)     4/13 (30.8)                                                                  
   4                           0                   0                                                                            
  N or M stage                                                                                                                  
   N0M0                        275/1609 (17.1)     3/13 (23.1)      .476                                                        
   N+ or M+                    1334/1609 (82.9)    10/13 (76.9)                                                                 
  Tumor thrombus                                                                                                                
   No thrombus                 1540/1595 (96.6)    9/13 (69.2)      .001                               1                        .010
   Thrombus                    55/1595 (3.4)       4/13 (30.8)                                         8.222    1.660-40.720    
  Tumor extrusion                                                                                                               
   Exophytic                   747/1572 (47.5)     5/12 (41.7)      .804                                                        
   Mesophytic                  394/1572 (25.1)     4/12 (33.3)                                                                  
   Endophytic                  431/1572 (27.4)     3/12 (25.0)                                                                  
  Preoperative Hb, g/dL                                                                                                         
   \>16                        107/1609 (6.7)      1/13 (7.7)       .593                                                        
   ≤16                         1502/1609 (93.3)    12/13 (92.3)                                                                 
  Preoperative platelet, /μL                                                                                                    
   \>400 × 10^3^               37/1609 (2.3)       2/13 (15.4)      .037                               7.745    1.146-52.368    .036
   ≤400 × 10^3^                1572/1609 (97.7)    11/13 (84.6)                                        1                        
  Preoperative NLR                                                                                                              
   ≥1.87                       757/1608 (47.1)     8/13 (61.5)      .298                                                        
   \<1.87                      851/1608 (52.9)     5/13 (38.5)                                                                  
  Preoperative CRP, mg/dL                                                                                                       
   \>0.5                       248/1225 (20.2)     6/9 (66.7)       .003                               3.613    0.753-17.343    .109
   ≤0.5                        977/1225 (79.8)     3/9 (33.3)                                          1                        

Abbreviations: ECOG, Eastern Cooperative Oncology Group; Hb, hemoglobin; NLR, neutrophil-to-lymphocyte ratio; CRP, C-reactive protein; CI, confidence interval.

^a^ Patients who were not diagnosed with stage IV at the initial diagnosis, n = 1622.

In multivariable analysis, older age (≥60 years), the presence of tumor thrombus, and increased preoperative CRP (\>0.5 mg/dL) were risk factors for an increased incidence of VTE when all patients were considered (odds ratio \[OR\] 8.608, *P* = .006 for age; OR 8.160, *P* = .016 for tumor thrombus; OR 4.144, *P* = .035 for preoperative CRP; [Table 2](#table2-1076029618823288){ref-type="table"}). In subgroup analysis of patients who were not diagnosed with stage IV at the initial diagnosis, older age (≥60 years), the presence of tumor thrombus, and increased preoperative platelet count (\>400 × 10^3^/μL) were associated with a significantly increased incidence of VTE in multivariable analysis (OR 14.935, *P* = .016 for age; OR 8.222, *P* = .010 for tumor thrombus; OR 7.745, *P* = .036 for preoperative platelets; [Table 3](#table3-1076029618823288){ref-type="table"}).

Survival Outcomes {#section10-1076029618823288}
-----------------

During follow-up, 5-year PFS and OS were 85.2% ± 0.9% and 87.7% ± 0.8%, respectively. In univariable analysis, older age, poor Eastern Cooperative Oncology Group (ECOG) status, papillary type, advanced T stage, the presence of lymph node or distant metastases, tumor thrombus, exophytic type, and elevated preoperative platelet count, NLR, and CRP were prognostic factors for poor PFS ([Table 4](#table4-1076029618823288){ref-type="table"}). In addition, age, ECOG status, histology, T stage, N or M stage, tumor thrombus, tumor extrusion, and preoperative hemoglobin, platelet count, NLR, and CRP were prognostic factors for OS in univariable analysis ([Table 5](#table5-1076029618823288){ref-type="table"}).

###### 

Hazard Ratios (HRs) and *P* Values of Progression-Free Survival (PFS) Using Cox Regression Analysis in Univariable and Multivariable Analyses.

![](10.1177_1076029618823288-table4)

                               Univariable Analysis   Multivariable Analysis                          
  ---------------------------- ---------------------- ------------------------ ------- -------------- --------
  Age, years                                                                                          
   ≥60                         82.2 (80.7-83.7)       \<.001                   1.153   0.857-1.551    .347
   \<60                        87.2 (86.1-88.3)                                1                      
  Gender                                                                                              
   Male                        84.8 (83.8-85.8)       .181                                            
   Female                      87.0 (85.6-88.4)                                                       
  Smoking                                                                                             
   Yes                         87.8 (85.8-90.8)       .387                                            
   No                          85.2 (84.3-86.1)                                                       
  ECOG                                                                                                
   0                           88.1 (87.2-89)         \<.001                   1                      .015
   1                           78.1 (76.1-80.1)                                1.509   1.106-2.059    .009
   2                           76.1 (71.1-81.1)                                1.695   0.997-2.882    .051
  Histology                                                                                           
   Clear cell type             84.4 (83.4-85.4)       .004                     1                      .222
   Papillary type              83.6 (80.8-86.4)                                0.996   0.642-1.544    .985
   Chromophobe                 92.1 (89.9-94.3)                                0.482   0.243-0.956    .037
   Others                      98.6 (97.2-100)                                 0                      .956
  T stage                                                                                             
   1                           91.5 (90.7-92.3)       \<.001                   1                      \<.001
   2                           71.4 (68.1-74.7)                                4.115   2.701-6.268    \<.001
   3                           55.0 (51.3-58.7)                                4.745   3.133-7.185    \<.001
   4                           0                                               8.750   3.919-19.534   \<.001
  N or M stage                                                                                        
   N0M0                        86.1 (85.2-87.0)       .003                     1                      .212
   N+ or M+                    77.4 (74.3-80.5)                                1.286   0.866-1.910    
  Tumor thrombus                                                                                      
   No thrombosis               88.0 (87.2-88.8)       \<.001                   1                      .001
   Thrombosis                  37.4 (32.6-42.2)                                1.916   1.295-2.834    
  Tumor extrusion                                                                                     
   Exophytic                   82.7 (81.4-84.1)       .001                     1                      .751
   Mesophytic                  84.4 (82.6-86.2)                                0.904   0.639-1.279    .569
   Endophytic                  90.4 (89.1-91.7)                                0.884   0.609-1.285    .519
  Preoperative Hb, g/dL                                                                               
   \>16                        88.4 (85.8-91.0)       .223                                            
   ≤16                         84.8 (83.9-85.7)                                                       
  Preoperative platelet, /μL                                                                          
   \>400 × 10^3^               51.1 (44.2-58.0)       \<.001                   1.253   0.780-2.011    .351
   ≤400 × 10^3^                86.4 (85.5-87.3)                                1                      
  Preoperative NLR                                                                                    
   ≥1.87                       78.6 (77.2-80.0)       \<.001                   1.710   1.201-2.435    .003
   \<1.87                      91.8 (90.9-92.7)                                1                      
  Preoperative CRP, mg/dL                                                                             
   \>0.5                       69.4 (66.4-72.4)       \<.001                   1.395   0.998-1.950    .051
   ≤0.5                        88.8 (87.6-90.0)                                1                      

Abbreviations: CI, confidence interval; CRP, C-reactive protein; ECOG, Eastern Cooperative Oncology Group; Hb, hemoglobin; NLR, neutrophil-to-lymphocyte ratio.

###### 

Hazard Ratios (HRs) and *P* Values of Overall Survival (OS) Using Cox Regression Analysis in Univariable and Multivariable Analyses.
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                               Univariable Analysis   Multivariable Analysis                          
  ---------------------------- ---------------------- ------------------------ ------- -------------- --------
  Age, years                                                                                          
   ≥60                         82.2 (80.7-83.7)       \<.001                   1.585   1.167-2.152    .003
   \<60                        91.2 (90.3-92.1)                                1                      
  Gender                                                                                              
   Male                        87.0 (86.0- 88.0)      .350                                            
   Female                      89.3 (87.9-90.7)                                                       
  Smoking                                                                                             
   Yes                         85.9 (83.7-88.1)       .687                                            
   No                          88.0 (72.2-88.8)                                                       
  ECOG                                                                                                
   0                           90.5 (89.7-91.3)       \<.001                   1                      .001
   1                           80.9 (82.9-78.9)                                1.478   1.062-2.057    .020
   2                           74.2 (69.1-79.3)                                2.401   1.457-3.959    .001
  Histology                                                                                           
   Clear cell type             87.3 (86.4-88.2)       \<.001                   1                      .026
   Papillary type              82.1 (79.3-84.9)                                1.612   1.043-2.492    .032
   Chromophobe                 93.3 (86.9-99.7)                                0.461   0.213-0.999    .050
   Others                      97.1 (95.8-98.4)                                0                      .966
  T stage                                                                                             
   1                           93.7 (93.0-94.4)       \<.001                   1                      \<.001
   2                           76.8 (73.7-79.9)                                3.078   1.950-4.857    \<.001
   3                           64.3 (61.1-67.5)                                4.221   2.704-6.591    \<.001
   4                           0                                               8.485   3.842-18.741   \<.001
  N or M stage                                                                                        
   N0M0                        88.1 (87.3-88.9)       .017                     1                      .046
   N+ or M+                    84.9 (82.2-87.6)                                1.550   1.009-2.381    
  Tumor thrombus                                                                                      
   No thrombosis               90.0 (89.2-90.8)       \<.001                   1                      .492
   Thrombosis                  52.3 (47.8-56.8)                                1.164   0.755-1.793    
  Tumor extrusion                                                                                     
   Exophytic                   84.2 (82.9-85.5)       \<.001                   1                      .894
   Mesophytic                  88.7 (87.3-90.1)                                1.058   0.738-1.519    .758
   Endophytic                  92.4 (91.2-93.6)                                0.951   0.637-1.418    .804
  Preoperative Hb, g/dL                                                                               
   \>16                        93.6 (91.8-95.4)       .007                     1                      .942
   ≤16                         87.1 (86.3-87.9)                                1.026   0.510-2.065    
  Preoperative platelet, /μL                                                                          
   \>400 × 10^3^               55.1 (48.8-61.4)       \<.001                   1.144   0.713-1.836    .577
   ≤400 × 10^3^                88.9 (88.1-89.7)                                1                      
  Preoperative NLR                                                                                    
   ≥1.87                       80.7 (79.4-82.0)       \<.001                   1.863   1.273-2.727    .001
   \<1.87                      94.8 (94.0-95.6)                                1                      
  Preoperative CRP, mg/dL                                                                             
   \>0.5                       88.8 (87.6-90.0)       \<.001                   3.101   2.217-4.336    \<.001
   ≤0.5                        93.8 (92.8-94.8)                                1                      

Abbreviations: CI, confidence interval; CRP, C-reactive protein; ECOG, Eastern Cooperative Oncology Group; Hb, hemoglobin; NLR, neutrophil-to-lymphocyte ratio.

Tumor thrombus was an independent factor for poor PFS but not for OS in the final multivariable analysis (hazard ratio \[HR\] 1.916, 95% CI, 1.295-2.834, *P* = .001 for PFS; HR 1.164, 95% CI, 0.755-1.793, *P* = .492 for OS; [Tables 4](#table4-1076029618823288){ref-type="table"} and [5](#table5-1076029618823288){ref-type="table"}, [Figure 2A and B](#fig2-1076029618823288){ref-type="fig"}). Poor ECOG status, advanced T stage, and increased preoperative NLR (≥1.87) were also associated with poor PFS in multivariable analysis (HR 1.509, *P* = .009 for ECOG 1; HR 4.115, *P* \< .001 for T2; HR 4.745, *P* \< .001 for T3; HR 8.750, *P* \< .001 for T4; HR 1.710, *P* = .003 for preoperative NLR; [Table 4](#table4-1076029618823288){ref-type="table"}). Additionally, older age, worse ECOG status, papillary type, advanced T stage, advanced N or M stage, and increased preoperative NLR (≥1.87) and CRP (\>0.5 mg/dL) were risk factors for worse OS in multivariable analysis (HR 1.585, *P* = .003 for age; HR 1.478, *P* = .020 for ECOG 1; HR 2.401, *P* = .001 for ECOG 2; HR 1.612, *P* = .032 for papillary type; HR 3.078, *P* \< .001 for T2; HR 4.221, *P* \< .001 for T3; HR 8.485, *P* \< .001 for T4; HR 1.550, *P* = .046 for N+ or M+ stage; HR 1.863, *P* = .001 for preoperative NLR; HR 3.101, *P \<* .001 for preoperative CRP; [Table 5](#table5-1076029618823288){ref-type="table"}).

![Survival outcomes according to the presence or absence of tumor thrombus: (A) progression-free survival (5-year survival: 88.0% vs 37.4%, *P* \< .001) and (B) overall survival (5-year survival: 90.0% vs 52.3%, *P* \< .001).](10.1177_1076029618823288-fig2){#fig2-1076029618823288}

Discussion {#section11-1076029618823288}
==========

Venous thromboembolism (VTE) is a risk factor for poor prognosis in patients with cancer; previous studies have reported that patients with VTE have a higher mortality rate than those without VTE.^[@bibr6-1076029618823288]^

In the present study, we found that patients with RCC tumor thrombus had an approximately 8-fold increased risk of VTE during follow-up. With the unique ability of RCC to produce tumor thrombus, the risk of VTE might increase as tumor thrombus enters the pulmonary circulation after surgery.^[@bibr18-1076029618823288]^ Furthermore, tumor thrombus can stimulate procoagulant factors through activation of vascular endothelial cells, which might contribute to an increased risk of VTE.^[@bibr14-1076029618823288]^ In a previous study, Ihaddadene et al reported that the incidence of VTE was higher in patients with residual tumor thrombus after surgery than in those with complete tumor thrombus resection or no tumor thrombus (HR 8.7, 95% CI, 1.7-43.4 for complete resection; HR 6.5, 95% CI, 1.7-24.7 for no thrombosis).^[@bibr17-1076029618823288]^ Our current findings are consistent with these results, as our patients with tumor thrombus had a higher incidence of thromboembolic events than those without thrombus. However, we did not classify patients according to whether they had residual tumor thrombus postoperatively. Nevertheless, we examined the effects of variables that could be related to VTE, such as smoking, tumor extent, inflammatory markers, and hemogram results.^[@bibr19-1076029618823288][@bibr20-1076029618823288][@bibr21-1076029618823288]--[@bibr22-1076029618823288]^ In addition, we performed subgroup analysis in patients who were not diagnosed with stage IV at the initial diagnosis because advanced stage is associated with increased biological activity of the tumor, and previous studies have reported that the biological aggressiveness of tumors could be positively correlated with thromboembolic events.^[@bibr7-1076029618823288],[@bibr21-1076029618823288]^ Our results show that tumor thrombus was one of the statistically significant risk factors for VTE in the total study population, as well as in the subgroup of patients who were not diagnosed with an advanced stage initially.

Although hemogram results, such as the platelet count and hemoglobin, were not associated with an increased incidence of VTE, older age and increased CRP were identified as risk factors for VTE in the present study. The CRP is a representative inflammatory marker; an inflammatory state could contribute to VTE through activation of vascular endothelial cells and adhesion molecules, which could activate the coagulation cascade.^[@bibr15-1076029618823288],[@bibr23-1076029618823288],[@bibr24-1076029618823288]^ Older age is an established risk factor for VTE, which may be associated with underlying illnesses or reduced blood flow and stasis that increase the potential for coagulation.^[@bibr25-1076029618823288]^

Renal cell carcinoma (RCC) is a type of malignancy frequently associated with the development of VTE, with a 1.3- to 5.3-fold higher risk of VTE than cancers with a low thromboembolic risk.^[@bibr9-1076029618823288],[@bibr26-1076029618823288]^ In the current study, the incidence of VTE was low (1%) compared to that found in previous studies.^[@bibr9-1076029618823288],[@bibr21-1076029618823288],[@bibr27-1076029618823288]^ This difference could be explained by the characteristics of our patients. We evaluated a homogeneous group of patients who had undergone surgery, most of whom (93.3%) did not have metastatic lesions. In malignant neoplasms, tumor cells can activate the hemostatic system and coagulation cascade through procoagulant factors, including tissue factor, cancer procoagulants, and inflammatory cytokines. Additionally, interaction of tumor cell surface adhesion molecules with platelets, leukocytes, and vascular endothelial cells can promote clotting activation and thrombus formation. Through these processes, tumor cells can promote the development of VTE. Additionally, procoagulant proteins can support the metastasis of tumors by promoting neoangiogenesis.^[@bibr26-1076029618823288]^ This synergistic interaction may explain the positive correlation between cancer biological activity and VTE formation.^[@bibr7-1076029618823288],[@bibr21-1076029618823288]^ Therefore, our patients likely had a relatively low incidence of VTE because of fewer biologically aggressive tumor features.

In the present study, we found that tumor thrombus predicted poor PFS but not OS. The effect of tumor thrombus on survival has been controversial in previous studies.^[@bibr13-1076029618823288],[@bibr17-1076029618823288],[@bibr28-1076029618823288],[@bibr29-1076029618823288]^ Ihaddadene et al reported that residual tumor thrombus was not associated with worse survival compared with those without a tumor thrombus or completely resected tumor thrombus, and their result is similar to the result in this study ^[@bibr17-1076029618823288]^. However, Haferkamp et al found that tumor thrombus extension was an independent prognostic factor for survival.^[@bibr13-1076029618823288]^ Therefore, further large-scale studies might be necessary to verify this.

Our study has some limitations, including its retrospective and single-center design. Therefore, our results should be interpreted with caution and will require validation in future prospective studies from other centers. Despite these limitations, this study clearly demonstrates that tumor thrombus is associated with an increased thromboembolic risk in patients who underwent surgery for RCC and that it has a negative impact on PFS.

In conclusion, the incidence of VTE was relatively low in patients with RCC who underwent surgery. Nevertheless, patients with tumor thrombus, older age, and increased preoperative CRP had a 4 to 8 times increased risk of VTE and should be monitored closely for the development of VTE.
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